EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis

Sunaina Advani iD, Advait Raja iD, Tatiana Giraldo iD, Sümeyye Aktaş, Ayomide Lawal, Alfonso Gotor iD

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag255 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Sunaina Advani und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA. Hauptthemen laut MEDLINE: Psoriasis, Peptides, Cyclic. Die Arbeit nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In biologic therapies targeting interleukin (IL)-23 for plaque psoriasis, parenteral administration can limit treatment adherence and quality of life. Icotrokinra is a first-in-class oral peptide that selectively antagonizes the IL-23 receptor and has shown promising efficacy in phase II and phase III trials. However, a comprehensive synthesis of efficacy and safety across these trials is currently lacking.

Objectives

To evaluate the efficacy and safety of icotrokinra in adolescents (12–17 years) and adults (≥ 18 years) with moderate-to-severe plaque psoriasis.

Methods

PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched on 8 December 2025, with reference lists hand-searched for additional studies. Randomized controlled trials enrolling the target population were included if they compared icotrokinra with placebo and reported efficacy or safety outcomes.

Results

Five randomized controlled trials (one phase II and four phase III), comprising four reports, met the inclusion criteria. Icotrokinra significantly increased the likelihood of achieving an Investigator’s Global Assessment score of 0 or 1 at week 16 compared with placebo (risk ratio 7.27, 95% confidence interval 5.80–9.11), with no heterogeneity (I2 = 0%). High-level skin clearance, represented by ≥ 90% improvement in Psoriasis Area and Severity Index, was also significantly improved (risk ratio 13.8, 95% confidence interval 7.21–26.5). Rates of treatment-emergent and serious adverse events were comparable between icotrokinra and placebo, with no new safety signals identified over the 16-week trial period.

Conclusions

Icotrokinra has shown short-term efficacy and a favourable safety profile in patients with moderate-to-severe plaque psoriasis. Combining biologic-level efficacy with ease of administration, icotrokinra may represent an important advance in psoriasis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPeptides, CyclicAdolescentAdultHumansQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment Outcome

Substanzen

icotrokinraPeptides, Cyclic

Autor:innen und Institutionen

  • School of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA.
  • Clinical School of Medicine, University of Cambridge, Cambridge, UK.
  • Medicina Intensiva del Tolima, UCI Honda, Honda, Colombia.
  • Department of Dermatology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
  • Department of Medicine, Mid and South Essex NHS Foundation Trust, Essex, UK.
  • Department of Dermatology, University Hospital '12 de Octubre', Madrid, Spain.

ORCID-Profile: Sunaina Advani, Advait Raja, Tatiana Giraldo, Alfonso Gotor

Zitieren

APA

Advani, S., Raja, A., Giraldo, T., Aktaş, S., Lawal, A., & Gotor, A. (2026). Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag255

Vancouver

Advani S, Raja A, Giraldo T, Aktaş S, Lawal A, Gotor A. Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag255

BibTeX
@article{Advani2026,
  author = {Advani, Sunaina and Raja, Advait and Giraldo, Tatiana and Aktaş, Sümeyye and Lawal, Ayomide and Gotor, Alfonso},
  title = {Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag255}
}
Kostenlos starten →